drugset / Trial / NCT03636750
A Study of Injection HB002.1T in Subjects With Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with solid tumor.
Timeline
- Start
- 2018-06-28
- Primary completion
- 2020-02-20
- Completion
- 2020-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB002.1T | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | HB002.1T | Protein / enzyme biologic | 4 mg/kg | Intravenous |
| Subject | HB002.1T | Protein / enzyme biologic | 8 mg/kg | Intravenous |
| Subject | HB002.1T | Protein / enzyme biologic | 12 mg/kg | Intravenous |
| Subject | HB002.1T | Protein / enzyme biologic | 16 mg/kg | Intravenous |
| Subject | HB002.1T | Protein / enzyme biologic | 20 mg/kg | Intravenous |